Watch ELTP. Know when insiders buy.
One email the day a filing lands. Free.
ELTP
ELITE PHARMACEUTICALS INC /NV/
0.25
−0.01 −3.85%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
61
WATCH · insiders 55, shorts 67
Insiders, 90 days
+$9K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $269.3MP/E 6.3DIV YIELD —FCF YIELD 6.51%REV TTM $141M +33.7%NET INCOME $56.7MNET CASH $5.9M52W 0.25 – 0.70SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | $32.4M | −19.5% | 41.7% | $7.5M | $5.9M | — | 0.01 | $10.1M | $809K | $9.3M | Aug 13 |
| Q4 2026 · Mar 31derived | $40.7M | +27.4% | 51.0% | $10.2M | $18.5M | +8.6% | 0.01 | $9.1M | $398K | $8.7M | Jun 29 |
| Q3 2026 · Dec 31 | $31.6M | +119.9% | 41.0% | $9M | $18.6M | — | 0.01 | −$5.3M | $206K | −$5.5M | Feb 17 |
| Q2 2026 · Sep 30 | $36.3M | +92.4% | 38.7% | $8.2M | $13.7M | — | 0.01 | $5.1M | $103K | $5M | Feb 17 |
| Q1 2026 · Jun 30 | $40.2M | +113.9% | 67.7% | $21.7M | −$5.9M | −1055.7% | -0.01 | $14.8M | $218K | $14.6M | Aug 13 |
| Q4 2025 · Mar 31derived | $32M | +78.3% | 54.1% | $11.2M | $17M | +411.1% | 0.02 | $3.9M | $754K | $3.2M | Jun 29 |
| Q3 2025 · Dec 31 | $14.4M | −7.6% | 42.6% | $1.1M | −$10.9M | −1642.0% | -0.01 | −$1.1M | $0 | −$1.1M | Feb 17 |
| Q2 2025 · Sep 30 | $18.9M | +33.4% | 43.4% | $3.5M | −$11M | −173.9% | -0.01 | $1.5M | $92K | $1.4M | Feb 17 |
| Q1 2025 · Jun 30 | $18.8M | — | 45.1% | $3.9M | $616K | — | 0.00 | $3.1M | $779K | $2.4M | Feb 17 |
| Q4 2024 · Mar 31derived | $17.9M | — | 45.2% | $3.7M | $3.3M | — | 0.00 | $2.1M | $404K | $1.7M | Jun 30 |
| Q3 2024 · Dec 31 | $15.5M | — | 45.3% | $3.5M | $706K | — | 0.00 | −$2.4M | — | — | Feb 13 |
| Q2 2024 · Sep 30 | $14.2M | — | 45.5% | $1.9M | $14.9M | — | 0.01 | −$236K | — | — | Feb 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | $148.9M | 50.4% | $49.1M | $44.9M | 30.1% | 0.03 | $23.7M | $926K | $22.8M | — | — |
| FY2025 · to Mar 31 | $84M | 47.7% | $19.6M | −$4.3M | -5.1% | 0.00 | $7.5M | $1.6M | $5.8M | — | — |
| FY2024 · to Mar 31 | $56.6M | 46.5% | $10.8M | $20.1M | 35.5% | 0.02 | −$3.2M | $810K | −$4M | — | — |
| FY2023 · to Mar 31 | $34.2M | 48.6% | $3.7M | $3.6M | 10.4% | 0.00 | $3.3M | $5.7M | −$2.4M | — | — |
| FY2022 · to Mar 31 | $32.3M | 45.9% | $5.1M | $8.9M | 27.6% | 0.01 | $6.5M | $499K | $6M | — | — |
| FY2021 · to Mar 31 | $25.4M | 46.8% | $2.1M | $5.1M | 20.0% | 0.00 | $3.2M | — | — | — | — |
Every number comes from ELITE PHARMACEUTICALS INC /NV/'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.